NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal

Aripiprazole for the treatment of schizophrenia in people aged 15-17

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
 Manufacturers/sponsors Bristol Myers Squibb, Otsuka Pharmaceuticals (aripiprazole) Patient/carer groups Action for Sick Children Afiya Trust Black Health Agency Carers UK Changes Children's Society Chinese Mental Health Association Chinese National Healthy Living Centre Confederation of Indian Organisations Counsel and Care Diverse Minds Equalities National Council Max Appeal Mental Health Foundation Mental Health Providers Forum MIND Muslim Council of Great Britain Muslim Health Network National Children's Bureau National Parent Partnership Network National Perceptions Forum Rethink SANE South Asian Health Foundation Specialised Healthcare Alliance Together UK Advocacy Network United Response WellChild 	 General Board of Community Health Councils in Wales British National Formulary Commissioning Support Appraisals Service Department of Health, Social Services and Public Safety for Northern Ireland Hafal Medicines and Healthcare products Regulatory Agency MIND Cymru National Association of Primary Care National Mental Health Development Unit National Public Health Service for Wales NHS Alliance NHS Confederation NHS Quality Improvement Scotland NHS Purchasing and Supply Agency Scottish Medicines Consortium Comparator manufacturers Actavis UK (risperidone) AstraZeneca (quetiapine) Dexcel Pharma (risperidone) Eli Lilly & Company (olanzapine) Janssen-Cilag (risperidone) Merz (clozapine) Novartis (clozapine) Sandoz (risperidone) Sanofi-aventis (risperidone) Teva UK (clozapine)

National Institute for Health and Clinical Excellence

Provisional matrix for the technology appraisal of aripiprazole for the treatment of schizophrenia in people aged 15-17 Issue date: January 2010 Page 1 of 4

Consultees	Commentators (no right to submit or appeal)
 Young Minds Professional groups Association for Young People's Health British Association for Counselling and Psychotherapy British Association for Psychopharmacology British Association of Behavioural and Cognitive Psychotherapies British Association of Psychotherapists British Confederation of Psychotherapists British Neuropsychiatry Association British Psychological Society Community Psychiatric Nurses Association Primary Care Mental Health Education Primary Care Mental Health Education Royal College of General Practitioners Royal College of Paediatrics and Child Health Royal College of Pathologists Royal College of Physicians Royal College of Physicians Royal College of Psychiatrists Royal Society of Medicine – Intellectual Disabilities Forum United Kingdom Clinical Pharmacy Association United Kingdom Council for Psychotherapy United Kingdom Psychiatric Pharmacy Group Others Department of Health Denbighshire LHB NHS Cambridgeshire Welsh Assembly Government 	 Cochrane Schizophrenia Group Institute of Psychiatry MRC Clinical Trials Unit National Institute for Health Research National Primary Care Research & Development Centre Evidence Review Group National Institute for Health Research Health Technology Assessment Programme Southampton Health Technology Assessment Centre (SHTAC), University of Southampton Associated Guideline groups National Collaborating Centre for Mental Health Associated Public Health groups tbc

National Institute for Health and Clinical Excellence Provisional matrix for the technology appraisal of aripiprazole for the treatment of schizophrenia in people aged 15-17 Issue date: January 2010 Page 2 of 4

NICE is committed to promoting equality and eliminating unlawful discrimination.

Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*.

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.